U.S.-based liquid biopsy company appoints China CEO for expansion
Irvine, Calif.-based Laboratory for Advanced Medicine, or LAM, has hired a China CEO to lead the company’s expansion into the country.
Samuel Tong joins LAM from medical research organization NAMSA. With previous stints at Qiagen, Becton Dickinson, and Abbott, Tong is tasked with commercializing LAM’s early cancer diagnostic tests for liver and colon cancer detection in Asia.
The company is focused on using methylation patterns of circulating free DNA in the blood as a way to detect cancer early, with clinical trials taking place in both China and the U.S.
With established facilities in Beijing and Guangzhou, LAM plans to expand significantly in the next two to three years to cover more than 50 cities and over 1,000 customers, including top hospitals, premium health check centers, and insurance companies, Tong told STAT.
“Although there are many competitors in the liquid biopsy field, only a few have focused on methylation technology. We are in the process of obtaining NMPA innovation and certificate approval in coming months for our liver cancer product. Once approved, LAM will be the only approved company by NMPA, differentiating LAM from other players,” Tong said.
Samuel Tong joins LAM from medical research organization NAMSA. With previous stints at Qiagen, Becton Dickinson, and Abbott, Tong is tasked with commercializing LAM’s early cancer diagnostic tests for liver and colon cancer detection in Asia.
The company is focused on using methylation patterns of circulating free DNA in the blood as a way to detect cancer early, with clinical trials taking place in both China and the U.S.
With established facilities in Beijing and Guangzhou, LAM plans to expand significantly in the next two to three years to cover more than 50 cities and over 1,000 customers, including top hospitals, premium health check centers, and insurance companies, Tong told STAT.
“Although there are many competitors in the liquid biopsy field, only a few have focused on methylation technology. We are in the process of obtaining NMPA innovation and certificate approval in coming months for our liver cancer product. Once approved, LAM will be the only approved company by NMPA, differentiating LAM from other players,” Tong said.
.png)
No hay comentarios:
Publicar un comentario